Cancer Research Horizons logo

Cancer Research Horizons

Europe, England, United Kingdom, London

Description

Cancer Research Horizons (CRT) develops and commercialises exciting new discoveries in cancer research.

Investor Profile

Cancer Research Horizons has made 9 investments, with 3 in the past 12 months and 11% as lead.

Stage Focus

  • Seed (67%)
  • Series A (11%)
  • Pre Seed (11%)
  • Series Unknown (11%)

Country Focus

  • United Kingdom (89%)
  • United States (11%)

Industry Focus

  • Health Care
  • Biotechnology
  • Therapeutics
  • Medical
  • Medical Device
  • Life Science
  • Artificial Intelligence (Ai)
  • Clinical Trials
  • Wellness
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Cancer Research Horizons frequently co-invest with?

Abingworth
Europe, England, United Kingdom, London
Co-Investments: 2
Martlet Capital
Europe, Cambridgeshire, United Kingdom, Cambridge
Co-Investments: 1
The Francis Crick Institute
Europe, England, United Kingdom, London
Co-Investments: 2
CA
Europe, Madrid, Spain, Madrid
Co-Investments: 1
Manta Ray Ventures
Europe, England, United Kingdom, London
Co-Investments: 1
SC
Europe, Kent, United Kingdom, Canterbury
Co-Investments: 1
Kindred Capital
Europe, England, United Kingdom, London
Co-Investments: 1
Octopus Ventures
Europe, England, United Kingdom, London
Co-Investments: 1
MA
Europe, Cambridgeshire, United Kingdom, Cambridge
Co-Investments: 2
Cancer Research Institute
North America, New York, United States, New York
Co-Investments: 1

Which angels does Cancer Research Horizons often collaborate with?

JM
North America, Massachusetts, United States, Cambridge
Shared Deals: 1

What are some of recent deals done by Cancer Research Horizons?

52 North Health

Cambridge, Cambridgeshire, United Kingdom

52 North Health is developing a fully-integrated clinical, AI-driven medical device-based system called NeutroCheck for people with cancer.

Artificial Intelligence (AI)Health CareMedical
Series UnknownDec 3, 2024
Amount Raised: $6,000,000
Myricx Bio

London, England, United Kingdom

Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.

BiotechnologyLife ScienceTherapeutics
Series AJul 8, 2024
Amount Raised: $115,311,437
Infinitopes

Oxford, Oxfordshire, United Kingdom

Infinitopes is developer of vaccines for the treatment of cancer.

Biotechnology
SeedApr 30, 2024
Amount Raised: $15,985,813
Neobe Therapeutics

London, England, United Kingdom

Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.

Clinical TrialsHealth CareMedicalTherapeutics
SeedFeb 29, 2024
Amount Raised: $2,340,000
NK:IO

London, England, United Kingdom

NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy.

BiotechnologyLife ScienceTherapeutics
SeedJul 25, 2023
Amount Raised: $1,547,243
Elaitra

San Francisco, California, United States

LLM BreastGPT; px engagement. ViewFinder; unique helping doctors read 3D X-Rays to diagnose breast cancer. USA & UK. FDA approved.

Artificial Intelligence (AI)Health CareMedical Device
Pre SeedJun 30, 2023
Amount Raised: $760,817
BioCaptiva

Edinburgh, Edinburgh, City of, United Kingdom

BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.

Health CareMedicalMedical Device
SeedJun 1, 2022
Amount Raised: $2,621,638
Achilles Therapeutics

London, England, United Kingdom

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

BiotechnologyHealth CareTherapeuticsWellness
SeedSep 28, 2016
Amount Raised: $17,215,632
GammaDelta Therapeutics

London, England, United Kingdom

GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells

BiotechnologyHealth CareHealth DiagnosticsTherapeutics
SeedSep 16, 2016